Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in CD30+ Lymphoproliferative Disorders
NCT04463615Phase 2Completed
- Sponsor
- City of Hope
- Start
- May 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leflunomide in Cutaneous CD30-positive lymphoproliferative disorder, sponsored by City of Hope. Primary endpoint: Overall Response Rate at 42 days. Started May 2021; status: completed.
02
Drugs
leflunomide
03
Conditions
Cutaneous CD30-positive lymphoproliferative disorder
Beyond the preview
Go deeper on NCT04463615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463615.